Skip to content

Life Sciences

MACO: from a health-based limit to a swab limit

  • Life Sciences
  • 1 min read

A swab limit in micrograms per 25 cm² starts life as one number for each pair of products: the MACO.

MACO is the maximum allowable carryover, the most of the previous product that may end up in a batch of the next one. The usual calculation, as in the APIC cleaning validation guidance: the PDE of the previous product, times the smallest batch of the next, divided by the next product's maximum daily dose.

Take a worked case: product A has a PDE of 10 µg/day. Product B has a minimum batch of 100 kg and a maximum daily dose of 2 g, so one batch holds 50,000 daily doses. MACO is 10 µg × 50,000 = 500 mg of A in the whole batch of B. Spread over 20 m² of shared product-contact surface that is 2.5 µg/cm², or 62.5 µg on a 25 cm² swab, before any recovery factor.

EU GMP Annex 15 (2015), clause 10.6, says limits for the carryover of product residues should be based on a toxicological evaluation, and that acceptance criteria should consider the cumulative effect of the items in the equipment train. The EMA guideline on health-based exposure limits gives the method for the PDE.

The shared surface area comes from equipment drawings, and if it is understated the limit per swab is too generous. A new product on the line means a new calculation: a smaller batch or a larger daily dose lowers the MACO of every product made before it.

Industries

Related

More on this subject

One more market is one more SKU to run

'Same product, new box' brings new artwork and codes to control, a registration that may need stability data at other climatic conditions, possibly a new pack to qualify, and one more changeover in the weekly plan. Cost the SKU as a small project before a launch date is promised.

InsightRead

Periodic evaluation is a review, not a rerun

EU GMP Annex 11 periodic evaluation asks whether a computerized system is still valid and compliant. Most of the evidence already exists in change control, deviation and incident records and the upgrade history. Review first, then retest only the functions the review shows are affected.

InsightRead

Pharmacopoeial methods still need verification

A pharmacopoeial method was validated before it was published, but not in your laboratory or on your product. EU GMP Chapter 6 says a laboratory that did not perform the original validation should verify the method's appropriateness, and WHO's validation guideline describes verification as partial validation, with specificity for the product shown.

InsightRead